Book chapter
Intravesical Salvage Therapy After BCG/Regular Chemo
Bladder Cancer, pp.111-121
Springer International Publishing
07/25/2021
DOI: 10.1007/978-3-030-70646-3_12
Abstract
High-risk, nonmuscle-invasive bladder remains one of the most expensive, recurrent, and frustrating diseases for the urologist in practice. BCG therapy is the mainstay of frontline therapy; however, recurrence will still occur for 40–80% of patients over a 10-year period. Radical cystectomy with urinary diversion remains the standard of care for many of these patients; however, recent evidence suggests that this is underutilized as many patients are either unfit for or unwilling to undergo such major extirpative therapy. Fortunately, there is a 6–24-month window of time after BCG to consider intravesical salvage therapy while not adversely affecting progression to muscle-invasive disease. In this chapter, practical guidance for the administration of several regimens including the expected side effects and cancer-specific outcomes is reviewed.
Details
- Title: Subtitle
- Intravesical Salvage Therapy After BCG/Regular Chemo
- Creators
- Michael A. O’Donnell - HoldenNathan A. Brooks - University of Iowa
- Resource Type
- Book chapter
- Publication Details
- Bladder Cancer, pp.111-121
- Publisher
- Springer International Publishing; Cham
- DOI
- 10.1007/978-3-030-70646-3_12
- Language
- English
- Date published
- 07/25/2021
- Academic Unit
- Urology
- Record Identifier
- 9984321546202771
Metrics
14 Record Views